Serum Caspase-3 and Caspase-7 as Predictive Factors of Response in Locally Advanced and Metastatic Breast Carcinoma

Hayma Hammoud, Jumana Saleh, Marroan Bachour, Maher Salamoon

Department of Medical Oncology, Al Bairouni University Hospital, Damascus, Syria.
Faculty of Pharmacy, Damascus University, Damascus, Syria.

DOI: 10.4236/jct.2014.56067                

Abstract

Introduction: Breast cancer is the most common cancer in women and the second most frequent cause of cancer death. Several factors affect response to chemotherapy including nodal status, hormonal status and human epidermal growth factor receptor (Her-2). Aim of Study: The study is aiming at evaluating Caspase-3, 7 levels in serum of patients with locally advanced and metastatic breast cancer and establishing the relation between Casepase level and response to chemotherapy. Patients and Methods: The study was performed at Al Bairouni University Hospital and the Faculty of Pharmacy (Damascus-Syria). We have included 60 patients with histologic confirmation of invasive ductal carcinoma of the breast treated with the combination (Docetaxel + Doxorubicin) with Caspase-3, 7 levels to be evaluated before treatment and 24 hours after the first and third cycle. Results: Caspase-3 level increases in serum 24 hours after the 1st cycle correlated with different kinds of response in 39 patients (P value 0.0002) with better results in those with Estrogen Receptors (ER) positive patients (P 0.005). In a similar manner, Caspase-7 level increases 24 hours after the 1st cycle correlated with response in 40 patients (P 0.005). However, ER status had no impact on response in Caspase-7 group (P 0.2). Conclusion: Caspase-3 and 7 levels in serum are useful as a predictive marker of response to chemotherapy in both locally advanced and metastatic breast cancer especially when tittered 24 hours after the first chemotherapy.

Keywords

Caspase-3, 7, Metastatic Breast Cancer, Response

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	Burstein Harold, J., Harris, J.R. and Monica, M. (2008) Malignant Tumors of the Breast. In: Devita, V.T., Lawrence, T.S. and Rosenberg, S.A., Eds., Cancer Principles & Practice of Oncology, 2, Williams and Wilkins, Wolters Kluwer Lippincott, 1606-1654.
[2]	Shahla, M. (2000) Assessment of Prognostic Factors in Breast Fine-Needle Aspirates. American Journal of Clinical Pathology, 113, S84-S96.
[3]	Gilmore, A.P., Metcalfe, A.M., Romer, L.H. and Streuli, C.H. (2000) Integrin-Mediated Survival Signals Regulate the Apoptotic Functions of Bax through Its Conformation and Subcellular Localization. The Journal of Cell Biology, 149, 431-445. http://dx.doi.org/10.1083/jcb.149.2.431
[4]	Lipponen, P. and Aaltomaa, S. (1994) Apoptosis in Bladder Cancer as Related to Standard Prognostic Factors and Prognosis. The Journal of Pathology, 73, 333-339. http://dx.doi.org/10.1002/path.1711730408
[5]	Stennicke, H.R. and Salvesen, G.S. (1998) Properties of the Caspases. Biochimica et Biophysica Acta, 1387, 17-31. http://dx.doi.org/10.1016/S0167-4838(98)00133-2
[6]	Thornberry, N.A. and Lazebnik, Y. (1998) Caspases: Enemies within. Science, 281, 1312-1316. http://dx.doi.org/10.1126/science.281.5381.1312
[7]	Keane, M.M., Ettenberg, S.A., Nau, M.M., Russell, E.K. and Lipkowitz, S. (1999) Chemotherapy Augments TRAIL- Induced Apoptosis in Breast Cell Lines. Cancer Research, 59, 734-741.
[8]	Bellarosa, D., Ciucci, A., Bullo, A., Nardelli, F., Manzini, S., Maggi, C. A. and Goso, C. (2001) Apoptotic Events in a Human Ovarian Cancer Cell Line Exposed to Anthracyclines. Journal of Pharmacology and Experimental Therapeutics, 296, 276-283.
[9]	Kottke, T.J., Blajeski, A.L., Martins, M., Mesner Jr., P.W., Davidson, N.E., Earnshaws, W.C., Armstrong, D.K. and Kaufmann, S.H. (1999) Comparison of Paclitaxel-, 5-Fluoro-2-deoxyuridine- and Epidermal Growth Factor (EGF)-In- duced Apoptosis. The Journal of Biological Chemistry, 274, 15927-15936. http://dx.doi.org/10.1074/jbc.274.22.15927
[10]	Suzuki, A., Kawabata, T. and Kato, M. (1998) Necessity of Interleukin-1β Converting Enzyme Cascade in Taxotere- Initiated Death Signaling. European Journal of Pharmacology, 343, 87-92. http://dx.doi.org/10.1016/S0014-2999(97)01520-3
[11]	Kerr, J.F., Winterford, C.M. and Harmon B.V. (1994) Apoptosis. Its Significance in Cancer and Cancer Therapy. Cancer, 73, 2013-2026. http://dx.doi.org/10.1002/1097-0142(19940415)73:8<2013::AID-CNCR2820730802>3.0.CO;2-J
[12]	Evan, G.I. and Vousden, K.H. (2001) Proliferation, Cell Cycle and Apoptosis in Cancer. Nature, 411, 342-348. http://dx.doi.org/10.1038/35077213
[13]	Yang, X.-H., Sladek, T.L., Liu, X., Butler, B.R., Froelich, C.J. and Thor, A.D. (2001) Reconstitution of Caspase 3 Sensitizes MCF-7 Breast Cancer Cells to Doxorubicin- and Etoposide-Induced Apoptosis. Cancer Research, 61, 348-354.
[14]	Scholl, S.M., Beuzeboc, P., Harris, A.L., et al. (1998) Is Primary Chemotherapy Useful for All Patients with Primary Invasive Breast Cancer? Recent results. Cancer Research, 152, 217-226. http://dx.doi.org/10.1007/978-3-642-45769-2_21
[15]	Holdenrieder, S. and Stieber, P. (2004) Apoptotic Markers in Cancer. Clinical Biochemistry, 37, 605-617. http://dx.doi.org/10.1016/j.clinbiochem.2004.05.003
[16]	Degterev, A. and Yuan, J. (2008) Expansion and Evolution of Cell Death Programmes. Nature Reviews Molecular Cell Biology, 9, 378-390. http://dx.doi.org/10.1038/nrm2393
[17]	Leers, M.P., Kolgen, W., Bjorklund, V., Bergman, T., et al. (1999) Immunocytochemical Detection and Mapping of a Cytokeratin 18 Neoepitope Exposed during Early Apoptosis. The Journal of Pathology, 187, 567-572. http://dx.doi.org/10.1002/(SICI)1096-9896(199904)187:5<567::AID-PATH288>3.0.CO;2-J
[18]	Olofsson, M.H., Ueno, T., Pan, Y., Xu, R., Cai, F., et al. (2007) Cytokeratin-18 Is a Useful Serum Biomarker for Early Determination of Response of Breast Carcinomas to Chemotherapy. Clinical Cancer Research, 13, 3198-3206. http://dx.doi.org/10.1158/1078-0432.CCR-07-0009
[19]	Meyn, R.E., Stephens, L.C., Hunter, N.R. and Milas, L. (1995) Apoptosis in Murine Tumors Treated with Chemotherapy Agents. Anticancer Drugs, 6, 443-450. http://dx.doi.org/10.1097/00001813-199506000-00013
[20]	Ellis, P.A., Smith, I.E., McCarthy, K., et al. (1997) Preoperative Chemotherapy Induces Apoptosis in Early Breast Cancer. Lancet, 349, 849. http://dx.doi.org/10.1016/S0140-6736(05)61752-7
[21]	Green, A.M. and Steinmetz, N.D. (2002) Monitoring Apoptosis in Real Time. Cancer Journal, 8, 82-92. http://dx.doi.org/10.1097/00130404-200203000-00002
[22]	Morse, D.L., Gray, H., Payne, C.M. and Gillies, R.J. (2005) Docetaxel Induces Cell Death through Mitotic Catastrophe in Human Breast Cancer Cells. Molecular Cancer Therapeutics, 4, 1495-504. http://dx.doi.org/10.1158/1535-7163.MCT-05-0130
[23]	Jordan, M.A.,Wendell, K., Gardiner, S., Derry, W.B., et al. (1996) Mitotic Block Induced in HeLa Cells by Low Concentrations of Paclitaxel (Taxol) Results in Abnormal Mitotic Exit and Apoptotic Cell Death. Cancer Research, 56, 816-825.
[24]	Blajeski, A.L., Kottke, T.J. and Kaufmann, S.H. (2001) A Multistep Model for Paclitaxel-Induced Apoptosis in Human Breast Cancer Cell Lines. Experimental Cell Research, 270, 277-288. http://dx.doi.org/10.1006/excr.2001.5349